Search citation statements
Paper Sections
Citation Types
Year Published
Publication Types
Relationship
Authors
Journals
Background: Thyrotoxicosis is a common endocrine disorder worldwide with a female predominance. Graves disease is reported as the commonest cause of thyrotoxicosis by various authors in the Africa region. Aims and Objectives: The study evaluated patient characteristics, clinical and laboratory profile, co-morbidities, treatment modalities, response to therapy, side effects of anti-thyroid medications, treatment outcome and complications of the disease in patients with thyrotoxicosis. Materials and methods: This study was retrospective and observational. The records of patients diagnosed with overt thyrotoxicosis seen in the Endocrine unit (2013-2017) were pulled and relevant data compiled. Data was analyzed using SPSS V 21. Results: A total of 172 cases were studied; 33 males and 132 females (ratio 1:4). They were aged 18-70; 40.2 ±12.5 years. Graves Disease constituted 79 % 0f cases and toxic multinodular goiter made up 18%. Seven cases of Marine Lenhart syndrome were identified. Graves orbitopathy occurred in 54%, but was mild. All but 6 patients received anti-thyroid medication as initial therapy mainly carbimazole (90%). About 6% had thyroidectomy. Treatment default was high (52%), while 15% remitted and 19% relapsed. Total duration of illness was 1-380, 40.7 ± 52.6 months. Drug rash occurred in 5% and cholestatic hepatitis in 1.8%. Hypertension coexisted in 35%. Six pregnancies were recorded, four of which ended in miscarriages, two of which had thyroid storm. Heart disease complicated the disease in 36%. Conclusion: Thyrotoxicosis is a common clinical condition. Treatment with carbimazole is effective. However the treatment default rate was very high. Coexisting hypertension and pronlonged period of untreated disease exposed patients to a high burden of heart disease. Patient education and introduction of radioablation therapy will mitigate these challenges.
Background: Thyrotoxicosis is a common endocrine disorder worldwide with a female predominance. Graves disease is reported as the commonest cause of thyrotoxicosis by various authors in the Africa region. Aims and Objectives: The study evaluated patient characteristics, clinical and laboratory profile, co-morbidities, treatment modalities, response to therapy, side effects of anti-thyroid medications, treatment outcome and complications of the disease in patients with thyrotoxicosis. Materials and methods: This study was retrospective and observational. The records of patients diagnosed with overt thyrotoxicosis seen in the Endocrine unit (2013-2017) were pulled and relevant data compiled. Data was analyzed using SPSS V 21. Results: A total of 172 cases were studied; 33 males and 132 females (ratio 1:4). They were aged 18-70; 40.2 ±12.5 years. Graves Disease constituted 79 % 0f cases and toxic multinodular goiter made up 18%. Seven cases of Marine Lenhart syndrome were identified. Graves orbitopathy occurred in 54%, but was mild. All but 6 patients received anti-thyroid medication as initial therapy mainly carbimazole (90%). About 6% had thyroidectomy. Treatment default was high (52%), while 15% remitted and 19% relapsed. Total duration of illness was 1-380, 40.7 ± 52.6 months. Drug rash occurred in 5% and cholestatic hepatitis in 1.8%. Hypertension coexisted in 35%. Six pregnancies were recorded, four of which ended in miscarriages, two of which had thyroid storm. Heart disease complicated the disease in 36%. Conclusion: Thyrotoxicosis is a common clinical condition. Treatment with carbimazole is effective. However the treatment default rate was very high. Coexisting hypertension and pronlonged period of untreated disease exposed patients to a high burden of heart disease. Patient education and introduction of radioablation therapy will mitigate these challenges.
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.
hi@scite.ai
10624 S. Eastern Ave., Ste. A-614
Henderson, NV 89052, USA
Copyright © 2024 scite LLC. All rights reserved.
Made with 💙 for researchers
Part of the Research Solutions Family.